<DOC>
	<DOCNO>NCT00005626</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . PURPOSE : Phase II trial study effectiveness irinotecan treating patient newly diagnose relapse non-Hodgkin 's lymphoma leukemia .</brief_summary>
	<brief_title>Phase II Trial With Correlative Laboratory Studies Single Agent Irinotecan ( Camptosar CPT-11 )</brief_title>
	<detailed_description>OBJECTIVES : I . Determine complete partial response rate patient newly diagnose relapsed indolent non-Hodgkin 's lymphoma , high risk chronic lymphocytic leukemia , prolymphocytic leukemia treat irinotecan . II . Determine toxicity regimen patient . III . Correlate level DNA topoisomerase I mRNA protein , well SN-38 induced topoisomerase I-DNA complex formation , clinical response toxicity patient . IV . Determine regulation topoisomerase I alter subcellular distribution enzyme involved drug resistance irinotecan . OUTLINE : Patients receive irinotecan IV 90 minute day 1 , 8 , 15 , 22 . Treatment repeat every 6 week 2-6 course absence disease progression unacceptable toxicity . Patients follow survival . PROJECTED ACCRUAL : A total 17-40 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically prove newly diagnose relapse nonHodgkin 's lymphoma ( NHL ) 1 follow type : Low grade ( diffuse small lymphocytic/marginal zone , grade I follicular small cleave cell , grade II follicular mixed cell ) OR Mantle cell OR Histologically proven newly diagnose relapse stage III IV chronic lymphocytic leukemia ( CLL ) prolymphocytic leukemia ( PLL ) At least 1 measurable disease parameter Enlarged spleen extend least 2 cm costal margin constitutes measurable disease provide explanation lymphomatous involvement likely Enlarged liver extend least 5 cm costal margin constitutes measurable disease Not allowable sole indication therapy : Isolated splenomegaly OR Isolated hepatomegaly No central nervous system ( CNS ) metastases carcinomatous meningitis A new classification scheme adult nonHodgkin 's lymphoma adopt PDQ . The terminology `` indolent '' `` aggressive '' lymphoma replace former terminology `` low '' , `` intermediate '' , `` high '' grade lymphoma . However , protocol us former terminology . PATIENT CHARACTERISTICS : Age : 18 Performance status : Eastern Cooperative Oncology Group ( ECOG ) 02 Life expectancy : At least 12 week Hematopoietic : NHL : Granulocyte count great 1,500/mm^3 Hemoglobin least 9.0 g/dL Platelet count great 100,000/mm^3 CLL PLL : Granulocyte count great 500/mm^3 Hemoglobin great 7.0 g/dL Platelet count great 50,000/mm^3 Hepatic : Bilirubin great 1.5 mg/dL SGOT great 3 time upper limit normal ( ULN ) ( great 5 time ULN liver tumor present ) No Gilbert 's disease Renal : Creatinine great 2.0 mg/dL OR Creatinine clearance least 60 mL/min Calcium le 12.0 mg/dL ( correct ) Cardiovascular : No myocardial infarction atrial fibrillation within past 6 month No congestive heart failure require therapy Other : No active uncontrolled infection HIV negative No psychiatric disorder would preclude informed consent compliance No malignancy within past 5 year except basal cell squamous cell skin cancer carcinoma situ cervix Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No history seizures No uncontrolled diabetes mellitus , define random blood glucose least 200 mg/dL No severe concurrent disease would increase risk PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior irinotecan topoisomerase I inhibitor ( e.g. , topotecan ) Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify Other : No concurrent phenytoin , phenobarbital , antiepileptic prophylaxis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>stage I grade 1 follicular lymphoma</keyword>
	<keyword>stage I grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>prolymphocytic leukemia</keyword>
	<keyword>stage I mantle cell lymphoma</keyword>
	<keyword>contiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>contiguous stage II mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>noncontiguous stage II marginal zone lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>stage I marginal zone lymphoma</keyword>
	<keyword>stage I small lymphocytic lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>contiguous stage II marginal zone lymphoma</keyword>
	<keyword>contiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>